Announcements Trials
Browse Landscape

Status

Completed 8Terminated 6Recruiting 4Active not recruiting 4Withdrawn 1Unknown 1Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

tempol 2balstilimab 2zolbetuximab 1zipalertinib 1venetoclax 1ulixertinib 1tisagenlecleucel 1tipifarnib 1tebentafusp 1talazoparib 1sodium thiosulfate 1selinexor 1ruxolitinib 1ribociclib 1osunprotafib 1nirogacestat 1mirdametinib 1lifileucel 1leronlimab 1idecabtagene vicleucel 1gedatolisib 1ensartinib 1dodecyl maltoside 1burosumab 1brexucabtagene autoleucel 1belantamab mafodotin 1axicabtagene ciloleucel 1asciminib 1anlotinib 1TEMPOL-H 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × INDUSTRY × Mitomycin × Clear all
NCT05494411 2025-02-28

Named Patient Program for Mitomycin for Pyelocalyceal Solution

UroGen Pharma Ltd.

Available
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡